Regeneron Pharmaceuticals, Inc. achieved positive results from the largest trial assessing any monoclonal antibody treatment in patients hospitalized with severe COVID-19. The UK RECOVERY trial found that adding investigational REGEN-COV (casirivimab and imdevimab) to usual care reduced the risk of death by 20% in patients who had not mounted a natural antibody response against SARS-CoV-2.   RECOVERY is the first trial large enough to definitively determine whether REGEN-COV reduces mortality ...